Tofacitinib as a Promising Therapeutic Option in Refractory Autoimmune-Mediated Vascular and Sclera Inflammation

Mediterr J Rheumatol. 2023 Sep 29;34(3):282-283. doi: 10.31138/mjr.20230929.taa. eCollection 2023 Sep.
No abstract available

Keywords: JAK inhibitors; Takayasu; autoimmune scleritis; tofacitinib.

Publication types

  • Editorial